Veracyte Announces that New Data from Multiple Studies Demonstrate “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis
Study findings reported at the American Thyroid Association Annual Meeting
Researchers from leading institutions presented posters showing that use of the Afirma GSC at their respective centers significantly increased the identification of benign thyroid nodules among those deemed indeterminate – not clearly benign or malignant – following cytopathology review, compared to the original Afirma test.
Ohio State University– Researchers compared results of 113 indeterminate samples that were tested with the Afirma GSC to those of 403 samples using the earlier version of the test (the Afirma Gene Expression Classifier, or GEC). The Afirma GSC identified 74.1 percent of the nodules as benign, compared to 48.4 percent with the GEC, an increase of 53 percent. The overall surgery rate among all patients who underwent genomic testing decreased by more than half – from 42.2 percent with the GEC to 20.2 percent with the GSC. Cleveland Clinic– Comparing results of 46 samples tested with the Afirma GSC between July 2017and December 2017with 182 samples tested with the original test between December 2011and July 2017, researchers found that the GSC identified 67.4 percent as benign, compared to 41.8 percent with the GEC – an increase of 61 percent. The overall surgery rate for nodules tested with the GSC was 32.6 percent, compared to 47.3 percent with the original test, a decrease of 31 percent.
- Brigham and Women’s Hospital – Researchers evaluated results for 583 thyroid nodules tested with either the Afirma GSC (n=97) or GEC (n=486) between 2011 and 2018. They found that the Afirma GSC identified 64.9 percent of nodules as benign, compared to 47.9 percent with the GEC, an increase of 35 percent.
“Our results show that with the improved testing, we sent significantly
fewer patients to surgery,” said Dr.
Additionally, in two oral presentations, researchers shared the first
“real world” Afirma Xpression Atlas data, providing insights into the
distribution of a wide range of gene variants and fusions across key
categories of indeterminate thyroid nodules and Afirma GSC results. For
example, among 13,549 indeterminate thyroid nodules evaluated using the
Afirma GSC and Xpression Atlas, more than a quarter (25.9 percent) of
GSC-suspicious nodules (in primary risk categories known as
“Having detailed genomic information about thyroid nodules that are
malignant or suspicious for cancer may in some cases help inform
surgical decision-making for these patients,” said Dr.
The field of precision medicine is progressing rapidly, and multiple targeted therapies are in clinical trials or have been approved for treatment of advanced cancers that harbor specific genomic alterations. In the new data presented at the ATA conference, genomic changes (or alterations) targeted by these new therapies were identified in Afirma GSC-suspicious cases by the Xpression Atlas.
“The new data shared at the ATA annual meeting add to the growing
library of real-world evidence demonstrating the Afirma GSC’s
performance across multiple institutions in reducing unnecessary
surgeries in thyroid cancer diagnosis,” said
For more information, please visit the Veracyte Booth #201 or www.afirma.com/ATA2018.
Veracyte’s Afirma solution provides a comprehensive offering in thyroid
cancer diagnosis for physicians evaluating patients with thyroid
nodules. The Afirma Genomic Sequencing Classifier combines RNA
sequencing data with machine learning to identify patients with benign
thyroid nodules among those with indeterminate cytopathology results in
order to avoid unnecessary surgery and preserve the thyroid. Since the
commercial introduction of Afirma in 2011,
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "expect," "believe," "should," "may,"
"will" and similar references to future periods. Examples of
forward-looking statements include, among others, our belief that our
genomic tests will transform the diagnosis of thyroid cancer, lung
cancer and idiopathic pulmonary fibrosis; statements about the ability
of Afirma GSC to improve upon the original Afirma test; and statements
about the accuracy of the Xpression Atlas. Forward-looking statements
are neither historical facts nor assurances of future performance.
Instead, they are based only on our current beliefs, expectations and
assumptions regarding the future of our business, future plans and
strategies, anticipated events and trends, the economy and other future
conditions. Forward-looking statements involve risks and uncertainties,
which could cause actual results to differ materially, and reported
results should not be considered as an indication of future performance.
These risks and uncertainties include, but are not limited to: our
ability to achieve
Veracyte Media & Investor Contact:
Angie McCabe, 650-243-6371
Vice President, Investor Relations & Corporate Communications